02657nas a2200289   4500000000100000008004100001260001200042653000800054653001700062653002000079653003400099653002500133653002400158653003500182653003700217653003300254653001400287100001500301700002300316700001600339700001400355245018300369856006300552300000900615520172900624022001402353       2024                            d  c08/202410aHIV10aMarkov model10aCervical cancer10acost‐effectiveness analysis10adecision tree models10aEconomic evaluation10afemale genital schistosomiasis10ahigh‐risk human papillomavirus10ahome‐based self‐sampling10aScreening1 aLamberti O1 aTerris-Prestholt F1 aBustinduy A1 aBozzani F00aA health decision analytical model to evaluate the cost-effectiveness of female genital schistosomiasis screening strategies: The female genital schistosomiasis SCREEN framework.  uhttps://onlinelibrary.wiley.com/doi/epdf/10.1111/tmi.14040  a1-103 a<p>Female genital schistosomiasis is a chronic gynaecological disease caused by the waterborne parasite Schistosoma (S.) haematobium. It affects an estimated 30-56 million girls and women globally, mostly in sub-Saharan Africa where it is endemic, and negatively impacts their sexual and reproductive life. Recent studies found evidence of an association between female genital schistosomiasis and increased prevalence of HIV and cervical precancer lesions. Despite the large population at risk, the burden and impact of female genital schistosomiasis are scarcely documented, resulting in neglect and insufficient resource allocation. There is currently no standardised method for individual or population-based female genital schistosomiasis screening and diagnosis which hinders accurate assessment of disease burden in endemic countries. To optimise financial allocations for female genital schistosomiasis screening, it is necessary to explore the cost-effectiveness of different strategies by combining cost and impact estimates. Yet, no economic evaluation has explored the value for money of alternative screening methods. This paper describes a novel application of health decision analytical modelling to evaluate the cost-effectiveness of different female genital schistosomiasis screening strategies across endemic settings. The model combines a decision tree for female genital schistosomiasis screening strategies, and a Markov model for the natural history of cervical cancer to estimate the cost per disability-adjusted life-years averted for different screening strategies, stratified by HIV status. It is a starting point for discussion and for supporting priority setting in a data-sparse environment.</p>  a1365-3156